Press briefing 1 Lung and Gynaecological cancers

Moderator and Commentator LBA5_PR: Pilar Garrido, Spain
Commentator LBA4_PR: Marina Garassino, Italy
Commentator LBA2_PR: Susana Banerjee, UK

Link to press releases and abstracts

More Press releases with links to abstracts:

LBA68_PR   5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma
1983PD_PR  Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients (pts) for targeted or immunotherapy treatment (tx) using the prospective CUPISCO trial’s criteria
LBA15_PR  A phase 3 trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary site (GEFCAPI 04)
LBA30_PR  Analysis of circulating tumor DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration
LBA91_PR  A multicenter randomized phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma (MPM) – results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
LBA81_PR[nbsp Phase II/III blood-first assay screening trial (BFAST) in treatment-naïve NSCLC: initial results from the ALK+ cohort